Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
Saved in:
| Title: | Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study. |
|---|---|
| Authors: | Craig TJ; Allergy, Asthma and Immunology, Department of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; Vinmec International Hospital, Hanoi, Vietnam. Electronic address: tcraig@pennstatehealth.psu.edu., Levy DS; Division of Allergy and Immunology, University of California, Irvine, CA, USA., Reshef A; Allergy, Immunology and Angioedema Center, Barzilai University Hospital, Ashkelon, Israel., Lumry WR; AARA Research Center, Dallas, TX, USA., Martinez-Saguer I; HZRM Haemophilia Center Rhein Main, Mörfelden-Walldorf, Germany., Jacobs JS; Allergy & Asthma Clinical Research, Walnut Creek, CA, USA., Yang WH; Ottawa Allergy Research Corporation, Department of Medicine, University of Ottawa, Ottawa, ON, Canada., Ritchie B; Division of Hematology, Department of Medicine, University of Alberta, Edmonton, AB, Canada., Aygören-Pürsün E; Department of Pediatrics, University Hospital, Goethe University Frankfurt, Frankfurt, Germany., Keith PK; McMaster University Medical Centre Site, Hamilton, ON, Canada., Busse P; Mount Sinai, New York, NY, USA., Feuersenger H; CSL Behring Innovation GmbH, Marburg, Germany., Alexandru Bica M; CSL Behring Innovation GmbH, Marburg, Germany., Jacobs I; CSL Behring, King of Prussia, PA, USA., Pragst I; CSL Behring Innovation GmbH, Marburg, Germany., Magerl M; Institute of Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Freie Universität Berlin, Berlin, Germany; Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany. |
| Source: | The Lancet. Haematology [Lancet Haematol] 2024 Jun; Vol. 11 (6), pp. e436-e447. Date of Electronic Publication: 2024 May 03. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38710185 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Craig+TJ%22">Craig TJ</searchLink>; Allergy, Asthma and Immunology, Department of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; Vinmec International Hospital, Hanoi, Vietnam. Electronic address: tcraig@pennstatehealth.psu.edu.<br /><searchLink fieldCode="AU" term="%22Levy+DS%22">Levy DS</searchLink>; Division of Allergy and Immunology, University of California, Irvine, CA, USA.<br /><searchLink fieldCode="AU" term="%22Reshef+A%22">Reshef A</searchLink>; Allergy, Immunology and Angioedema Center, Barzilai University Hospital, Ashkelon, Israel.<br /><searchLink fieldCode="AU" term="%22Lumry+WR%22">Lumry WR</searchLink>; AARA Research Center, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Martinez-Saguer+I%22">Martinez-Saguer I</searchLink>; HZRM Haemophilia Center Rhein Main, Mörfelden-Walldorf, Germany.<br /><searchLink fieldCode="AU" term="%22Jacobs+JS%22">Jacobs JS</searchLink>; Allergy & Asthma Clinical Research, Walnut Creek, CA, USA.<br /><searchLink fieldCode="AU" term="%22Yang+WH%22">Yang WH</searchLink>; Ottawa Allergy Research Corporation, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Ritchie+B%22">Ritchie B</searchLink>; Division of Hematology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.<br /><searchLink fieldCode="AU" term="%22Aygören-Pürsün+E%22">Aygören-Pürsün E</searchLink>; Department of Pediatrics, University Hospital, Goethe University Frankfurt, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Keith+PK%22">Keith PK</searchLink>; McMaster University Medical Centre Site, Hamilton, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Busse+P%22">Busse P</searchLink>; Mount Sinai, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Feuersenger+H%22">Feuersenger H</searchLink>; CSL Behring Innovation GmbH, Marburg, Germany.<br /><searchLink fieldCode="AU" term="%22Alexandru+Bica+M%22">Alexandru Bica M</searchLink>; CSL Behring Innovation GmbH, Marburg, Germany.<br /><searchLink fieldCode="AU" term="%22Jacobs+I%22">Jacobs I</searchLink>; CSL Behring, King of Prussia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Pragst+I%22">Pragst I</searchLink>; CSL Behring Innovation GmbH, Marburg, Germany.<br /><searchLink fieldCode="AU" term="%22Magerl+M%22">Magerl M</searchLink>; Institute of Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Freie Universität Berlin, Berlin, Germany; Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101643584%22">The Lancet. Haematology</searchLink> [Lancet Haematol] 2024 Jun; Vol. 11 (6), pp. e436-e447. <i>Date of Electronic Publication: </i>2024 May 03. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101643584 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2352-3026 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223523026%22">23523026 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Haematol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38710185 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S2352-3026(24)00081-4 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e436 Titles: – TitleFull: Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Craig TJ – PersonEntity: Name: NameFull: Levy DS – PersonEntity: Name: NameFull: Reshef A – PersonEntity: Name: NameFull: Lumry WR – PersonEntity: Name: NameFull: Martinez-Saguer I – PersonEntity: Name: NameFull: Jacobs JS – PersonEntity: Name: NameFull: Yang WH – PersonEntity: Name: NameFull: Ritchie B – PersonEntity: Name: NameFull: Aygören-Pürsün E – PersonEntity: Name: NameFull: Keith PK – PersonEntity: Name: NameFull: Busse P – PersonEntity: Name: NameFull: Feuersenger H – PersonEntity: Name: NameFull: Alexandru Bica M – PersonEntity: Name: NameFull: Jacobs I – PersonEntity: Name: NameFull: Pragst I – PersonEntity: Name: NameFull: Magerl M IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2024 Jun Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2352-3026 Numbering: – Type: volume Value: 11 – Type: issue Value: 6 Titles: – TitleFull: The Lancet. Haematology Type: main |
| ResultId | 1 |
